Do analysts rate CARM or STAB?

Carisma Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 5,960.61%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Statera Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Statera Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, CARM or STAB?

Statera Biopharma has lower revenue, but higher earnings than Carisma Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Carisma Therapeutics $10.77M 0.06 -$60.48M $0.73 0.02 Statera Biopharma N/A N/A N/A N/A N/A

Is CARM or STAB more profitable?

Statera Biopharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics -254.28% N/A -192.17% Statera Biopharma N/A N/A N/A

Which has higher earnings and valuation, CMRA or STAB?

Statera Biopharma has lower revenue, but higher earnings than Comera Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Comera Life Sciences $1.00M 0.00 -$18M -$0.31 N/A Statera Biopharma N/A N/A N/A N/A N/A

Is CMRA or STAB more profitable?

Company Net Margins Return on Equity Return on Assets Comera Life Sciences N/A N/A N/A Statera Biopharma N/A N/A N/A

Which has stronger valuation and earnings, EFTR or STAB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eFFECTOR Therapeutics N/A N/A -$35.81M -$13.08 N/A Statera Biopharma N/A N/A N/A N/A N/A

Is EFTR or STAB more profitable?

Company Net Margins Return on Equity Return on Assets eFFECTOR Therapeutics N/A N/A N/A Statera Biopharma N/A N/A N/A

Which has better earnings & valuation, EVLO or STAB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evelo Biosciences N/A N/A -$114.53M -$8.81 N/A Statera Biopharma N/A N/A N/A N/A N/A

Is EVLO or STAB more profitable?

Company Net Margins Return on Equity Return on Assets Evelo Biosciences N/A N/A N/A Statera Biopharma N/A N/A N/A

Which has better earnings and valuation, STAB or CALA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Statera Biopharma N/A N/A N/A N/A N/A Calithera Biosciences N/A N/A -$39.65M N/A N/A

Is STAB or CALA more profitable?

Company Net Margins Return on Equity Return on Assets Statera Biopharma N/A N/A N/A Calithera Biosciences N/A N/A N/A

Statera Biopharma (STAB) Competitors

$0.0001 0.00 (0.00%)

As of 06/10/2026 12:15 PM Eastern

Compare

STAB vs. CARM, CMRA, EFTR, EVLO, and CALA

Should you buy Statera Biopharma stock or one of its competitors? MarketBeat compares Statera Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Statera Biopharma include Carisma Therapeutics (CARM), Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), Evelo Biosciences (EVLO), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry.

How does Statera Biopharma compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Statera Biopharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Statera Biopharma	N/A	N/A	N/A

44.3% of Carisma Therapeutics shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 5.5% of Statera Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Carisma Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

Carisma Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 5,960.61%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Statera Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Statera Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Statera Biopharma has lower revenue, but higher earnings than Carisma Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.06	-$60.48M	$0.73	0.02
Statera Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Statera Biopharma	Neutral

Summary

Carisma Therapeutics beats Statera Biopharma on 9 of the 11 factors compared between the two stocks.

How does Statera Biopharma compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Company	Net Margins	Return on Equity	Return on Assets
Comera Life Sciences	N/A	N/A	N/A
Statera Biopharma	N/A	N/A	N/A

Comera Life Sciences has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Statera Biopharma has lower revenue, but higher earnings than Comera Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Comera Life Sciences	$1.00M	0.00	-$18M	-$0.31	N/A
Statera Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Comera Life Sciences	Neutral
Statera Biopharma	Neutral

Summary

Comera Life Sciences beats Statera Biopharma on 3 of the 3 factors compared between the two stocks.

How does Statera Biopharma compare to eFFECTOR Therapeutics?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
eFFECTOR Therapeutics	N/A	N/A	N/A
Statera Biopharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eFFECTOR Therapeutics	N/A	N/A	-$35.81M	-$13.08	N/A
Statera Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company	Overall Sentiment
eFFECTOR Therapeutics	Neutral
Statera Biopharma	Neutral

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by insiders. Comparatively, 5.5% of Statera Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

eFFECTOR Therapeutics has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Summary

eFFECTOR Therapeutics beats Statera Biopharma on 3 of the 4 factors compared between the two stocks.

How does Statera Biopharma compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evelo Biosciences	N/A	N/A	-$114.53M	-$8.81	N/A
Statera Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Evelo Biosciences	Neutral
Statera Biopharma	Neutral

Evelo Biosciences has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

0.3% of Evelo Biosciences shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by company insiders. Comparatively, 5.5% of Statera Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Evelo Biosciences	N/A	N/A	N/A
Statera Biopharma	N/A	N/A	N/A

Summary

Evelo Biosciences beats Statera Biopharma on 3 of the 4 factors compared between the two stocks.

How does Statera Biopharma compare to Calithera Biosciences?

Statera Biopharma (NASDAQ:STAB) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company	Overall Sentiment
Statera Biopharma	Neutral
Calithera Biosciences	Neutral

Statera Biopharma has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Statera Biopharma	N/A	N/A	N/A	N/A	N/A
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Statera Biopharma	N/A	N/A	N/A
Calithera Biosciences	N/A	N/A	N/A

Summary

Statera Biopharma and Calithera Biosciences tied by winning 1 of the 2 factors compared between the two stocks.

Get Statera Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STAB vs. The Competition

Export

Metric	Statera Biopharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1K	$766.95M	$6.50B	$11.95B
Dividend Yield	N/A	4.84%	2.67%	5.61%
P/E Ratio	0.00	1.46	24.41	23.63
Price / Sales	N/A	134.54	496.61	94.22
Price / Cash	N/A	20.06	43.05	54.72
Price / Book	N/A	7.93	10.40	6.70
Net Income	N/A	-$4.69M	$3.56B	$337.26M
7 Day Performance	N/A	-2.04%	-3.02%	-2.46%
1 Month Performance	N/A	3.96%	-0.41%	0.31%
1 Year Performance	N/A	93.62%	20.03%	23.15%

Statera Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
STAB Statera Biopharma	N/A	$0.00 flat	N/A	+0.0%	$1K	N/A	N/A	20
CARM Carisma Therapeutics	2.4655 of 5 stars	$0.00 flat	$1.00 +999,900.0%	-98.5%	$4K	$10.77M	0.00	20
CMRA Comera Life Sciences	N/A	N/A	N/A	N/A	$3K	$1.00M	N/A	2
EFTR eFFECTOR Therapeutics	N/A	$0.00 flat	N/A	+0.0%	$3K	N/A	N/A	10
EVLO Evelo Biosciences	N/A	N/A	N/A	-40.0%	$2K	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STAB) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Statera Biopharma (STAB) Competitors

STAB vs. CARM, CMRA, EFTR, EVLO, and CALA

How does Statera Biopharma compare to Carisma Therapeutics?

Summary

How does Statera Biopharma compare to Comera Life Sciences?

Summary

How does Statera Biopharma compare to eFFECTOR Therapeutics?

Summary

How does Statera Biopharma compare to Evelo Biosciences?

Summary

How does Statera Biopharma compare to Calithera Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STAB vs. The Competition

Statera Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Statera Biopharma (STAB) Competitors

STAB vs. CARM, CMRA, EFTR, EVLO, and CALA

How does Statera Biopharma compare to Carisma Therapeutics?

Is CARM or STAB more profitable?

Do insiders and institutionals believe in CARM or STAB?

Which has more risk and volatility, CARM or STAB?

Do analysts rate CARM or STAB?

Which has preferable valuation & earnings, CARM or STAB?

Does the media favor CARM or STAB?

Summary

How does Statera Biopharma compare to Comera Life Sciences?

Is CMRA or STAB more profitable?

Which has more risk & volatility, CMRA or STAB?

Which has higher earnings and valuation, CMRA or STAB?

Does the media prefer CMRA or STAB?

Summary

How does Statera Biopharma compare to eFFECTOR Therapeutics?

Is EFTR or STAB more profitable?

Which has stronger valuation and earnings, EFTR or STAB?

Does the media refer more to EFTR or STAB?

Do insiders and institutionals have more ownership in EFTR or STAB?

Which has more volatility and risk, EFTR or STAB?

Summary

How does Statera Biopharma compare to Evelo Biosciences?

Which has better earnings & valuation, EVLO or STAB?

Does the media prefer EVLO or STAB?

Which has more risk & volatility, EVLO or STAB?

Do institutionals & insiders hold more shares of EVLO or STAB?

Is EVLO or STAB more profitable?

Summary

How does Statera Biopharma compare to Calithera Biosciences?

Does the media prefer STAB or CALA?

Which has more risk & volatility, STAB or CALA?

Which has better earnings and valuation, STAB or CALA?

Is STAB or CALA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STAB vs. The Competition

Statera Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools